AAV2-GDNF, ProHance, 279,3 mg/ml (0,5 mmol/ml), roztwór do wstrzykiwan clinical trials

Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

This study is looking at a new way to deliver a potential treatment, called AB-1005, for Parkinson's disease. Researchers want to make sure the delivery method is safe and works well. They'll also check if the treatment itself causes any side effects.